Algert Global LLC Sells 2,450 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Algert Global LLC decreased its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 7.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 30,256 shares of the company’s stock after selling 2,450 shares during the quarter. Algert Global LLC’s holdings in Kymera Therapeutics were worth $1,432,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of KYMR. Vanguard Group Inc. raised its holdings in Kymera Therapeutics by 19.2% during the 1st quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock valued at $191,635,000 after acquiring an additional 769,486 shares during the period. American International Group Inc. increased its holdings in shares of Kymera Therapeutics by 6.4% in the first quarter. American International Group Inc. now owns 20,095 shares of the company’s stock worth $808,000 after purchasing an additional 1,209 shares during the period. California State Teachers Retirement System increased its holdings in shares of Kymera Therapeutics by 5.5% in the first quarter. California State Teachers Retirement System now owns 40,423 shares of the company’s stock worth $1,625,000 after purchasing an additional 2,102 shares during the period. Comerica Bank increased its holdings in shares of Kymera Therapeutics by 13.7% in the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after purchasing an additional 400 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of Kymera Therapeutics in the first quarter worth $207,000.

Insider Buying and Selling

In related news, Director Pamela Esposito sold 13,500 shares of the stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 15.82% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently weighed in on KYMR shares. Morgan Stanley upped their price target on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 6th. Guggenheim upped their target price on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Leerink Partnrs upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. Wells Fargo & Company upped their target price on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. Finally, Wolfe Research upgraded shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 target price for the company in a research report on Monday, August 26th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $52.13.

Kymera Therapeutics Trading Up 1.9 %

Kymera Therapeutics stock opened at $46.86 on Friday. The firm has a 50-day moving average of $46.88 and a 200-day moving average of $42.11. The firm has a market cap of $3.03 billion, a P/E ratio of -20.03 and a beta of 2.21. Kymera Therapeutics, Inc. has a 1-year low of $19.11 and a 1-year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. The company had revenue of $3.74 million during the quarter, compared to analyst estimates of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Kymera Therapeutics’s revenue for the quarter was down 20.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.90) earnings per share. Research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.